Skip to main content

Table 5 Discriminant validity

From: Implementing electronic patient reported outcomes in inflammatory bowel disease: patient participation, score reliability and validity

Patient characteristic

Model (ANOVA)

Marginal means (IBD-Control-8)

Variable

Groups

N

%

F(df)

Prob > F

b

95% CI

Age

18–45

1267

40.4%

15.5(2)

P < 0.001

10.6

10.3

10.8

45–65

1368

43.6%

11.2

11.0

11.5

65 to max

503

16.0%

11.9

11.5

12.3

Gender

Male

1443

46.0%

29.77(1)

P < 0.001

11.6

11.3

11.8

Female

1695

54.0%

10.7

10.4

10.9

IBD type

CD

1626

51.8%

19.8(2)

P < 0.001

10.6

10.4

10.8

UC

1427

45.5%

11.6

11.4

11.9

Unclassified

85

2.7%

10.8

9.8

11.8

*Biologic treatment

No

2225

70.9%

163.2(1)

P < 0.001

11.7

11.6

11.9

Yes

913

29.1%

9.4

9.1

9.7

  1. Group differences were tested for the initial IBD-Control scores (N = 3138)
  2. Marginal means are for IBD-Control-8 scores (0–16 scale)
  3. *Biologic treatment was defined as having purchased at least one biologic medication including: Vedolizumab, Infliximab, Adalimumab, Ustekinumab, Golimumab, Tofacitinib, or Certolizumab
  4. b beta coefficient, df degrees of freedom, CD Crohn's disease; UC Ulcerative Colitis
Back to article page

Health and Quality of Life Outcomes

ISSN: 1477-7525

Contact us